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3-bromopyruvateTumors usurp established metabolic steps used by normal tissues for glucose utilization and ATP production that
rely heavily on mitochondria and employ a route that, although involving mitochondria, includes a much greater
dependency on glycolysis. First described by Otto Warburg almost nine decades ago [1], this aberrant phenotype
becomes more pronounced with increased tumor malignancy [2]. Thus, while maintaining their capacity for
respiration, tumors “turn more parasitic” by enhancing their ability to scavenge glucose from their surroundings.
With excess glucose at hand, tumors shunt theirmetabolicﬂuxmore toward glycolysis than do their normal cells of
origin, a strategy that allows for their survivalwhenoxygen is limitingwhile providing themamechanism to poison
their extra-cellular environment with acid, thus paving the way for invasion and metastasis. Signiﬁcantly, tumors
harness a crucial enzyme to regulate and support this destructive path—to entrap and channel glucose toward
glycolysis. This enzyme is an isoformof hexokinase, referred to as hexokinase type II, and also in abbreviated formas
HK-2 or HK II. Due tomany-facetedmolecular features at genetic, epigenetic, transcriptional, and enzymatic levels,
including sub-cellular localization to mitochondria, HK-2 facilitates and promotes the high glycolytic tumor
phenotype [3]. Thus, HK-2 represents a pivotalmodel gene or enzyme that tumors “select for”during tumorigenesis
inorder to facilitate theirdestructivepath. In this review,weexamine the rolesplayedbymitochondrial boundHK-2
within the context of the highly choreographedmetabolic roulette ofmalignant tumors. Recent studies that outline
how the aberrant glycolytic ﬂux can be subverted toward a more “normal” metabolic phenotype, and how the
glycolytic ﬂux affects the tumor microenvironment to facilitate tumor dissemination are also described, including
how these very features can be harnessed in new metabolic targeting strategies to selectively debilitate tumors.an endowment by Marvin E.
1CA08018 and R01CA010951.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
1.1. Tumor mitochondria and the associated enzymes and transporters
that commit many tumors toward a highly glycolytic phenotype
A universally observed clinical phenotype of highly malignant
tumors is their propensity to rapidly proliferate and spread (metas-
tasize) within the tumor-bearing host. Although numerous molecular
strategies are harnessed by the tumor to enable them to behave in this
insidious manner, a crucial component required is the tumor's ability
to usurp inordinate amounts of glucose from the host's blood, which
in turn is used by the tumor not only to grow, but to also poison its
surroundings in order to create a “molecular wasteland” around the
tumor, into which it can gradually “metastasize” [4–6].This propensity to metabolize glucose at excessive rates is the only
requirement, and the basis behind the clinical imaging and staging of
tumors via positron emission tomography (PET) [7,8]. Despite the
universality of this technique, study of the “bioenergetic” basis behind
this phenotype has not been examined that frequently or commonly by
the scientiﬁc community during the past several decades, except for a
few laboratories, one exempliﬁed by a coauthor of this contribution [9].
However, with the advent of new interest in the use of metabolic
pathways as useful molecular tools to target tumors, the ﬁeld has been
expanding at a rapid rate in recent years. This review will examine the
cellular features in tumors that facilitate the high glycolytic phenotype
in malignant tumors, and discuss the possible therapeutic avenues that
can be explored in view of ﬁndings from research that has been
conducted for the past several decades and continues to this day.
Signiﬁcantly, a study of metabolism in living cells goes back over
100 years to the time of Pasteur, when he described the phenomenon of
“fermentation”, i.e., that, in order to survive, cells switch from oxidative
phosphorylation (“respiration”) to glycolysis (fermentation) in the
absence of adequate oxygen. This phenotype is commonly referred to as
“anaerobic glycolysis”, or as the “Pasteur Effect.” Almost seven decades
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demonstrating that it occurred even in the presence of adequate oxygen
[1,10,11]. This aberrant metabolic feature, also found in rapidly
proliferating tumor cells, is now termed the “Warburg Effect” and
describes the propensity ofmalignant tumor cells to consumeglucose at
abnormally elevated rates and then metabolize and efﬂux most of it as
lactic acid to the surrounding cellular environment [2,4,12]. As opposed
to the Pasteur Effect, the latter is termed “aerobic glycolysis.” Clearly,
fermentation is an inferior and counter-intuitive method to generate
energy by a rapidly proliferating tumor cell; yet, it remains a universal
phenotype, indicating that other, “non-bioenergetic-based” selective
forces are active within the tumor and the tumor-microenvironment to
promote this aberrant behavior [13].
It should be emphasized that while malignant tumors have acquired
a high glycolytic phenotype, enhancing their glucose uptake by almost
10-fold, their respiration rate remains essentially unchanged from that
of surrounding normal tissue, a point eloquently outlined by Koppenol
and Bounds in a recent letter to Science [14]. Thus, while a normal cell
may synthesize (under normoxia) approximately 32 ATPmolecules per
glucose molecule, a highly glycolytic tumor may produce an additional
three fourths of this ATP via glycolysis (2 ATP molecules per glucose
molecule). Studies by numerous laboratories to date indicate that this
extra glucose intake is most likely diverted by tumors to biosynthetic
pathways for fatty acid synthesis and nucleotide synthesis to support
their rapid proliferation [4,13]. Thus, when bioenergetic capacity is
considered, tumors are as sufﬁcient in energy generation in comparison
to the surrounding normal tissues, if not more.
The key sub-cellular and molecular players that propel the tumor
toward this metabolic transformation can be distilled to a few select
enzymes; notably hexokinase, several mitochondrial associated
enzymes and plasmamembrane transporters, and the crucial organelle
involved in energy generation, the mitochondrion.
We will ﬁrst examine the membrane transporters that facilitate
inﬂux of glucose and efﬂux of lactic acid by such tumors, and then
describe the mitochondrial-bound hexokinase which acts as a
molecular sentinel to coordinate mitochondrial function (ATP
generation) and the cytoplasmic glycolytic ﬂux in order for the
tumor to rapidly proliferate in the tumor-bearing host.
2. Facilitators of glucose entry and lactate/proton efﬂux in
malignant tumors – glucose, lactate and proton transporters
2.1. Facilitated inﬂux of glucose
Of the various isoforms of glucose transporters (GLUT) which
passively transport glucose across the plasma membrane, several have
been implicated to be highly expressed in tumors. Although varying in
their kinetic properties for glucose transport, it should be noted that due
to the passive nature of glucose entry by these transporters, it is the
enzyme hexokinase (discussed later; found predominantly bound to
mitochondria in tumors) that “traps” incoming glucose by phosphory-
lation to impart an ionic charge, and then initiates the entire glycolytic
cascade. Thus, in order to enhance glucose entry, a tumor can “evolve”
two possible phenotypes; an obvious ﬁrst step would be to increase the
expression of plasma membrane glucose transporters; a second
possibility is to switch the glucose transporter isoforms to those that
have a higher afﬁnity for glucose. In fact, there have been numerous
reports of enhanced expression of glucose transporters in tumors
[15–17], with over 10-fold enhancement in their expression levels.With
regard to altered expression of transporters that have a higher afﬁnity, of
the currently recognized 12 isoforms of GLUT, it is the isoforms 3 and 4
that have thehighest afﬁnity for glucose [16]. Not surprisingly, bothhave
been shown to be over-expressed inmosthumancancers [15]. However,
GLUT1, ubiquitously expressed in all normal tissues, is one of the
commonly observed over-expressed isoforms in tumors, along with
GLUT3 and GLUT4. Thus, it may be that a partial GLUT isoform shiftoccurs during tumorigenesis, with the “normal” form being maintained
albeit at an elevated level in most tumors. This is in marked contrast to
hexokinase (discussed later) where a signiﬁcant isoform switch occurs
during tumorigenesis, especially in case of liver derived tumors.2.2. Facilitated efﬂux of lactic acid
The high ﬂux through the glycolytic pathway makes it necessary
for the tumor cell to rapidly remove lactic acid, the end product of
aerobic glycolysis. Previously thought to be removed via passive
diffusion across the plasma membrane in its protonated (charge
neutral—undissociated) form, it is now known that a family of
transmembrane transporters denoted as monocarboxylate transpor-
ters (MCTs) [18] are involved in facilitated efﬂux of lactic acid to the
tumor microenvironment [12]. Among the at least fourteen MCTs that
have been identiﬁed via the human genome project, only the ﬁrst four
(MCTs 1–4) have been experimentally veriﬁed to transport lactate
across the plasma membrane. Of the four isoforms, the MCT2 and
MCT4 have the highest afﬁnity for lactate, while MCT1, ubiquitously
expressed among normal tissues, has the lowest afﬁnity. In a manner
similar to that observed for glucose transporters, MCT1 is found over-
expressed among tumors, along with MCT2 and 4. Thus, the tumors
mirror their selective expression of MCTs vis-a-vis GLUT, with the
“normal” isoform being maintained at a higher level, along with co-
expression of high afﬁnity lactate transporters to maximize the lactate
removal to the tumor microenvironment.2.3. Active transport of protons to the tumor microenvironment—pumps
that facilitate tumor proliferation?
It is commonly observed that the microenvironment surrounding
highly malignant tumors has a lower pH in relation to that within the
tumor. This is in stark contrast to the physiological conditions
observed between normal tissues and their surroundings, even
during hypoxia, where the tissue will have a lower pH, while the
surroundings harbor a higher pH. Thus, such tumors play an active
role in reversing the pH proﬁle between the tumor and its
microenvironment to maintain a hostile pH towards the surrounding
normal tissue, which in turn may facilitate tumor dissemination as
well as invasion [5,6,19]. Which molecules are involved in facilitating
this “reversed” pH gradient in tumors?While the lactate transporter is
the sole transmembrane channel (symporter) responsible for elim-
ination of lactate produced via glycolysis with release of equivalent
amounts of protons, several other transmembrane transporters may
play an even greater role, both in facilitating and maintaining this
hostile phenotype. Biochemically, an energy expenditure will be
required by the tumors to maintain an adverse pH gradient towards
the microenvironment. Accordingly, several transmembrane mole-
cules, notably the sodium/proton exchanger (NHE), the chloride/
bicarbonate exchanger, the proton/chloride co-transporter, and the
transmembrane carbonic anhydrases (CA) in concert play a key role in
maintaining this adverse transmembrane pH gradient in tumors
[20,21] (Fig. 1).3. The enemywithin—tumormitochondria, their bound hexokinase
and the role of both in maintaining the high glycolytic phenotype
of tumors
Although the plasma membrane proteins discussed above facili-
tate glucose inﬂux into the tumor or proton and lactate efﬂux, the key
cellular components responsible for coordinating the high glycolytic
ﬂux across the tumor as well as bioenergetic homeostasis belongs to
the mitochondrion and the enzyme hexokinase II found bound
primarily to its outer membrane (OMM) [22–25].
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In fact, the critical step of trapping and committing the incoming
glucose to theglycolytic cascade in a tumor cell is facilitatedvia this crucial
phenotype well observed in malignant tumors; that of direct/close
interaction of hexokinase II with mitochondrial outer membrane porins
(VDACs, voltage gated anion channels) to facilitate access of mitochon-




This essentially irreversible metabolic ﬁrst step of the glycolytic
cascade entraps and commits incoming glucose to initiate the
glycolytic ﬂux across the tumor cell. In addition to mitochondrial
binding, tumors have optimized for maximum efﬁciency of glucose
turnover via utilization of additional molecules and selective "switch-
ing" of gene isoforms.
3.2. The enzymology of tumor hexokinase II
Of the four known isoforms of mammalian hexokinases [26,27], it
is isoforms I to III that harbor a signiﬁcantly higher afﬁnity for glucose
(∼250-fold higher). Thus, not surprisingly, malignant tumors switch
their hexokinase expression pattern predominantly to one of these
high-afﬁnity isoforms. This is seen clearly in the case of rapidly
growing hepatomas; whereas normal liver expresses glucokinase (orFig. 1. Themultifaceted events of a tumor cell that require a high glycolytic rate for both tumor
bioenergetic (ATP) requirements and biosynthetic requirements as follows: (A) Both glycolysi
oxidative phosphorylation [supportedbyNADHand FADHnot shown] derived from the TCAcyc
meet the tumor's energy (ATP) requirements. (B) The high glycolyticﬂux initiated and facilitate
metabolites for both RNA/DNA biosynthesis and fatty acid synthesis. These are essential for tum
efﬂuxof both lactic acid andprotons, the tumor creates a “poisonous” environment for the surrou
can slowly encroach. [Abbreviations: ETC, electron transport chain; PIC, phosphate carrier; ANT
glucose-6-phosphate;OAA, oxaloacetic acid.] (Note: TheATP synthase is nowknown to be in com
to give an ATP synthase/PIC/ANC complex called the “ATP synthasome” (Ref.: Ko, Y.H., Delannhexokinase IV), which has a high Km (∼5 mM; low afﬁnity) for
glucose [3], the hepatoma predominantly express the type II isoform.
The hexokinase types I–III appear to be duplication products of an
ancestral gene similar to the current glucokinase [27,28]. Thus, while
glucokinase is comprised of a single protein domain, the hexokinases
harbor twin domains. Among the three high afﬁnity hexokinase
isoforms, type II hexokinase harbors the potential for an enhanced
glucose turnover rate due to another crucial biochemical phenotype
related to the twin domains; although the three hexokinases are
composed of two nearly identical protein domains, each with the
potential to catalyze the phosphorylation of glucose, in hexokinases
type I and III, the N-terminal domain has lost its catalytic role and
acquired a regulatory role, thus subjecting these enzyme isoforms to
feedback regulation by ADP, inorganic phosphate and by glucose-
6-phosphate. In contrast, with type II hexokinase retaining the
catalytic capacity in both domains [29], the isoform effectively retains
the capacity to double the rate of formation of glucose-6-phosphate,
relative to isoforms I and III. Therefore, it is not surprising that type II
hexokinase is the isoform predominantly expressed in highly
malignant tumors [30,31].
Another crucial feature that is common at least to hexokinases I
and II are their N- termini which are hydrophobic. This allows these
enzymes to anchor themselves to the outer mitochondrial membrane
via porins (VDACs; voltage-gated anion channels) to gain immediate
access to mitochondrial generated ATP [32]. In addition, binding of
hexokinase II in this capacity almost completely prevents its productsurvival and proliferation:Many tumor cells require a high rate of glycolysis tomeet both
s (glucose to lactate pathway), initiated by mitochondrial bound hexokinase (green), and
le and terminatingwith theATP synthase F1 headpiece (red)] result in thenecessaryATP to
d byG-6-P formation viamitochondrial bound hexokinase (green) also leads to additional
or cell proliferation resulting in the subjugation of the surrounding normal tissue. (C) By
ndingnormal tissue,most likely topromote a "death zone" around the tumor intowhich it
, adenine nucleotide transporter (carrier); VDAC, voltage dependent anion channel; G-6-P,
plex formationwith thephosphate carrier (PIC) and the adenine nucleotide carrier (ANC)
oy, M., Hullihen, J., Chiu, W., and Pedersen, P.L. (2003) J. Biol. Chem. 278, 12305-12309).
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drial bound enzyme to initiate and thenmaintain a high glycolytic ﬂux
rate in tumors.
3.3. The genetics and epi-genetics behind overexpression of hexokinase II
in tumors
Malignant tumors also inﬂuence their hexokinase II expression
levels via both genetic and epi-genetic alterations to facilitate its
overexpression; at the gene level, both normal and tumor hexokinase
II harbor nearly identical transcriptional regulatory sequences.
However, ﬂuorescence in situ hybridization (FISH) studies have
indicated that tumors amplify the hexokinase II gene by at least 5-fold
[34]. Furthermore, epigenetic changes, i.e., methylation of the
hexokinase II promoter is observed in case of normal liver, indicating
that the gene is silenced, at least in part, in this manner in normal
tissues [35]. When the proximal promoter sequence of hexokinase II is
analyzed, several other features that support its expression even
under the most adverse physiological conditions within a tumor also
become evident. For example, the most proximal cis-elements in the
promoter are those for cyclic AMP (thus, the protein kinase A
pathway, upregulated by glucagon during starvation), an unexpected
feature, as the hexokinases should be up-regulated via increased
glucose levels (and protein kinase C pathway, and insulin) [36]. The
promoter also harbors the latter elements as well as those for hypoxia
(HIF-1) and tumor suppressor p53 [37,38]. Physiological analyses
have indicated that all these elements are active in the hexokinase II
promoter. Thus, these crucial features present a genetic survival
mechanism in these malignant tumors which enable them to
overexpress hexokinase II under “any” adverse physiological or
metabolic condition, in order to scavenge glucose from the host's
systemic circulation for the tumor's beneﬁt [4].
Overall, the above described genetic, epigenetic and biochemical
features may be common to most other key enzymes along the
glycolytic metabolic pathway, as most tumors “switch” to the fetal
type isoforms of these enzymes. These in turn enable the tumor to
maximize its ability to harness and channel key metabolites at the
expense of surrounding tissues, which commonly express the “adult”
or “differentiated” types of isoforms that are usually subjected to
feedback regulation at the enzyme level (or their gene expression
patterns are tightly regulated by the physiological condition of the
tumor bearing host). Thus, by shifting to the fetal isoforms, the tumors
bypass many of the biochemical constraints that regulate metabolism,
in order to maximize their survival at great expense to the host.
4. Tumor mitochondria—the central coordinating organelle of
tumor metabolism, survival and proliferation
The textbook explanation of themitochondrion is that it is primarily
a site for ATP generation. Although accurate, the anaplerotic and
cataplerotic metabolic ﬂuxes across mitochondria and the mitochon-
drial tricarboxylic acid cycle (TCA) all serve to coordinate several key
metabolic pathways crucial for tumor proliferation. For example,
synthesis of glutamine via the TCA cycle and NH4+, the pentose
phosphate shunt (that produces ribose-5-phosphate used for down-
stream synthesis of RNA and DNA via incorporation of glutamine and
bicarbonate), and synthesis of fatty acids via acetyl coenzyme A
generated from citrate, all function to provide biosynthetic precursors
necessary for the tumor's rapid proliferation [39]. The mitochondrion
also functions as a key regulator of numerous cellular functions critical
for cell survival [40]. Although the metabolic emphasis in tumors has
shifted to glycolysis, the mitochondrion also plays a key role in
controlling the metabolic ﬂuxes within the tumor cell. Thus, while as
much as 40% to 75% of ATP generation in a malignant tumor may occur
via glycolysis, themitochondria still function to generate the remainder
of the tumor's energy requirements.With direct coupling of mitochondrial generated ATP to incoming
glucose via VDAC (porin) bound hexokinase, mitochondria regulate
the extra-mitochondrial glycolytic ﬂux with that of the TCA cycle and
ATP synthase, to balance the energy requirements of the tumor cell
with the biochemical requirements for metabolites (anaplerotic and
cataplerotic pathways) or metabolite precursors that are required by
the tumor. Thus, both the glycolytic pathway and other seminal
metabolic pathways i.e., the pentose phosphate shunt, are regulated
via the energy coupling resulting from the VDAC bound hexokinase
complex.
5. Molecular choreography between glycolysis, respiration, reversed
pH and their impact on tumor survival and dissemination
If a “starting-point” for the initiation of the glycolytic cascade is to
be considered, it will be the ﬁrst stepwhere glucose is phosphorylated
by hexokinase to commit this key metabolite to the glycolytic
pathway. Here, hexokinase, bound to mitochondrial outer membrane
via VDAC, is provided preferential access to the mitochondrial ATP via
the adenine nucleotide translocator (ANT) in the IMM to rapidly and
quantitatively phosphorylate and “trap” the incoming glucose,
essentially initiating and regulating the glycolytic ﬂux across the
tumor cytosol. The resultant glycolytic metabolic cascade will provide
the tumor but with 2 net ATP molecules per phosphorylated glucose
molecule, with the remainder of the tumor's energy requirements
being met by the mitochondria, perhaps involving in part the
metabolism of glutamine [41].
The second crucial regulatory step of the glycolytic metabolic ﬂux
occurs at the outer membrane of mitochondria, when pyruvate enters
the mitochondrion to initiate the TCA cycle (via the yet to be
characterized pyruvate transporter?). Here, the pyruvate can enter the
mitochondrion, or be shuttled to the lactate dehydrogenase (LDH)
complex to be reduced to lactate and efﬂuxed to the tumor microenvi-
ronment, with concomitant oxidation (and cycling) of NADH toNAD+ to
ensure the continuation of the glycolytic cascade (Fig. 1). Signiﬁcantly,
not only are both pyruvate kinase (PK) and lactate dehydrogenase (LDH)
up-regulated by hypoxia (HIF-1) (and thus can channel the glycolytic
cascade toward lactate) [42], pyruvate dehydrogenase kinase (PDK), a
keymodulator of pyruvate dehydrogenase complex activity (PDH;which
serves as the gatekeeper for entry of pyruvate intomitochondria), is also
up-regulated by hypoxia [43]. Thus, HIF-1-mediated effects act in a
synergistic manner to veer the glycolytic cascade towards lactate
generation. However, it is still not clear as to whether the same effects
are in play in tumors that are under normoxic or near normoxic
conditions. Overall, the above effects effectively channel the tumor cell's
glycolytic ﬂux towards generation of lactic acid to be efﬂuxed to the
tumor microenvironment. In fact, recent reports indicate that extrusion
of protons by the tumor to the tumor microenvironment to reduce
extracellular pH may be a crucial strategy by tumors to promote their
invasiveness and proliferation [20,21].
Thus, close coupling between the proton-motive forces across the
mitochondrial membranes and the plasma membrane will be a
necessity for a tumor cell to efﬂux protons to the microenvironment,
in order to maintain a reduced pH in the extracellular milieu.
Therefore, a close coordination must exist between key metabolic
pathways of the tumor and mitochondrial functions in order for both
glycolysis and adverse ΔpH gradients across the plasma membrane to
be maintained by the tumor.
6. Therapeutic strategies against tumors targeted at their aberrant
metabolic ﬂux
The aberrant metabolic pathways that exist within the tumor as
well as reported altered pH proﬁles within the tumor microenviron-
ment provide new therapeutic strategies to be used against tumors
while leaving the surrounding normal tissue relatively unscathed.
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are being tested in Phase I–III clinical trials. These are brieﬂy discussed
below. A more thorough review of the various potential small-
molecule drugs that can be used to target the glycolytic pathway is
given in a recent review by Sheng and co-workers [44].
An obvious ﬁrst choice to block the initiating steps of glycolysis
(Fig. 1)wouldbe theuse of analogs of 18F-deoxy glucose (FDG) routinely
used in PET imaging of tumors where the non-hydrolyzable analog is
prevented from advancing beyond the hexokinase mediated phosphor-
ylation step. Thus, deoxyglucose [45], and two other direct inhibitors of
hexokinase, Lonidamine [46] and 3-bromopyruvate [47,48] have been
successfully tested in pre-clinical trials against malignant tumors. Of
these, 3-bromopyruvate was shown to be especially effective, eradicat-
ingadvanced tumors in 19/19 animals,withoutharm to the animals and
without return of the tumors during their life.
Pyruvate kinase is another key enzyme along the glycolytic
pathway, which involves an essentially irreversible step of converting
phosphoenolpyruvate (PEP) to pyruvate, prior tomitochondrial entry.
Thus, it also has presented a suitable drug target to debilitate tumors.
Several analogs of PEP have been developed and tested against tumors
to test their effects in inhibiting tumor proliferation [49,50].
Several other attractive targets are presented at the metabolic
routes immediately adjacent to mitochondrial pyruvate entry. These
involve lactate dehydrogenase (LDH) and an enzyme that regulates
the activity of pyruvate dehydrogenase (PDH), pyruvate dehydroge-
nase kinase (PDK). Both LDH and PDK have been targeted [51,52], the
former utilizing interference RNA techniques, while the latter has
been successfully targeted using di-choloroacetate (DCA), an analog
of pyruvate, with Phase II/III clinical trials ongoing at one medical
center [53,54].
Targeting lactate efﬂux is another avenue to inhibit the overall
glycolytic pathway to bring about tumor cell-death. This has been
successfully tested pre-clinically against malignant tumors both in vitro
and in vivo utilizing both interference RNA techniques and the small-
molecule drug alpha cyano 4-hydroxy cinnamic acid (ACCA), to bring
about tumor apoptosis and necrosis. In addition, the targeted tumors
showed increased sensitivity to radiation treatments, indicating
increased susceptibility of such tumors upon debilitation of the
glycolytic cascade [12,55,56].
Recent reports indicate that neutralizing the low pH of the tumor
microenvironment via physiological buffers (in this case bicarbonate)
can reduce the invasiveness of tumors and thus minimize the incidence
of distant metastases [57]. Denoted bicarbonate therapy, it has been
experimentally shown that the treatment reduced tumor presence in
lymphnodes in select in vivomodel systems. Thus, these studies openup
new avenues to control proliferation of malignant tumors via targeting
the low pH of the tumor microenvironment, perhaps bymodulating the
effects of plasma membrane transporters including the sodium/proton
exchanger, various bicarbonate exchangers, proton/chloride co-trans-
porters and the plasma membrane carbonic anhydrases [21,58]. Thus,
focused targeting of various key steps in the glycolytic pathway of tumor
cells to either inhibit the metabolic ﬂux, or to re-route it towards
mitochondrial respiration has shown positive results in controlling
tumor malignancy in both pre-clinical and Phase II/III clinical stages.
7. Conclusions
When the war on cancer was ﬁrst declared over four decades ago,
targetingmetabolism should have been an obviousﬁrst choice, asmany
research groups had at that time, a better understanding of the
biochemical signatures of cancers. However, with the advent of
molecular biology and signal transduction research, metabolism-based
researchwas discarded to the “backbenches”, except in a few dedicated
laboratories. With the increasing understanding of the difﬁculty in
targeting signal transduction of tumors without signiﬁcant side-effects,
cancer research is being redirected towards targeting the aberrantmetabolism of tumors. Already, signiﬁcant results have been achieved
by various research groups where multiple “points” on key metabolic
pathwayshavebeen targeted,with both small-molecule drugs aswell as
via interference RNA methodology. A key feature that needs to be used
as amolecular “yardstick” to judge the success of these endeavorswould
be to identify to what extent the hexokinase II catalyzed metabolic step
is directly impacted or not. Certainly, in the initial study by Ko et al. [48]
showing that 3-bromopyruvate is a potent anti-tumor agent, it was
shown to markedly inhibit tumor hexokinase.References
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